Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Press Releases

10 Feb 2022

Mindstate Design Labs Launches to Create the Next Generation of Psychedelic Therapeutics

Mindstate Design Labs Launches to Create the Next Generation of Psychedelic Therapeutics Emerging from Y Combinator’s S21 cohort with $11....

By Microdose

Press Releases

4 Feb 2022

Special Newswire Offer for Presenting Companies

InvestorWire is providing a special offer to expand the distribution of any announcement....

By Microdose

Psychedelic Titans

3 Feb 2022

Psychedelic Titans with Nathaniel Morris of PeyoteLab.com

This week's Psychedelic Titan is Nathaniel Morris, Peyote horticulturist and researcher for PeyoteLab....

By Microdose

Industry

2 Feb 2022

PharmaTher Granted FDA Orphan Drug Status for Ketamine

Following up on the recent news that PharmaTher Receives FDA Approval for Ketamine Phase 2 Trial, we now have PharmaTher receving orphan drug status for ketamine to a rare neurological...

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

27 Jan 2022

ATAI Launches Discovery Program for Next-Gen Mental Health Treatments

This new platform company is a further step-up in atai’s commitment to next-generation treatment...

By Microdose

Finance

20 Jan 2022

Eleusis: New Psychedelic Player Coming to the NASDAQ

Private firm Eleusis to go public on NASDAQ with upcoming merger...

By Microdose

Events

20 Jan 2022

The LSD Conference: A Molecular Masterclass – Call for Speakers

Microdose Psychedelic Insights (“Microdose”), your guide to the business of psychedelics, in partnership with MindBio Therapeutics a clinical-stage drug development company conducting research into microdosing and medicinal use of psychedelic...

By Microdose

Industry

19 Jan 2022

Awakn Life Sciences Signs MOU With MAPS

Agreement to explore a partnership for MDMA-Assisted Therapy for treatment of Alcohol Use Disorder in Europe...

By Microdose

Press Releases

19 Jan 2022

Enveric Biosciences CEO, Dr. Joseph Tucker, Provides 2021 Year in Review and 2022 Outlook in Letter to Shareholders

Enveric launched as a patient-centric biotechnology company, employing innovation and scientific leadership as core principles....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.